Key facts
- Cortechs.ai’s last known valuation is $49.0M.
- It has raised $23.1M; the latest was Later Stage VC ($14.0M) in Nov 2024.
- Notable investors include National Institutes of Health, CONNECT(San Diego), Vitalis Ventures, Dragasac Limited, Genting — 11 tracked in total.
- Status: Privately Held (backing).
Investors
11+- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Cortechs.ai
- ·The full record, as it builds
Funding rounds
No funding rounds for Cortechs.ai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cortechs.ai
Developer of AI-powered imaging analysis software designed to optimise diagnostics for neurological and oncological conditions. The company's platform features pre- and post-operative 3D volume analysis of brain tumours, automated quantification of tracer activity, lesion segmentation and longitudinal tracking using multiple MRI modalities, and enhanced prostate MRI analysis, enabling medical institutions worldwide to access quantitative imaging insights that support clinical and research decision-making in brain and prostate health conditions.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 1996
- Employees
- 59
- Website
- cortechs.ai/
- Ownership
- Privately Held (backing)
Cortechs.ai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cortechs.ai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cortechs.ai in its N-PORT filings yet. We sweep new filings monthly.